FDA approved area labeling revisions.

On July 10, the FDA approved area labeling revisions for olsalazine sodium capsules (Dipentum; UCB, Inc) to warn of drug interactions with heparin products, 6-mercaptopurine, and thioguanine, and cialis soft.

Concomitant use of salicylates, such as olsalazine, and low-molecular-weight heparins or heparinoids may event in an increased risk of bleeding (ie, hematomas) after neuraxial anesthesia. Salicylates should therefore be discontinued before the knowledgeability of a low-molecular-weight heparin or heparinoid; if this is not possible action, patients should be closely monitored for bleeding.

The FDA also warned that coadministration of olsalazine and 6-mercaptopurine or thioguanine can step-up the risk for myelosuppression. Patients receiving olsalazine and 6-mercaptopurine should receive the lowest opening doses of each drug and be carefully monitored, especially for leukopenia. Careful monitoring of pedigree counts is advised for those receiving olsalazine with thioguanine.
This is a part of article FDA approved area labeling revisions. Taken from "Bactrim Information" Information Blog